References
- Wang A, Green JB, Halperin JL, et al. Atrial fibrillation and diabetes mellitus: JACC review topic of the Week. J Am Coll Cardiol. 2019;74(8):1107–1115. doi: 10.1016/j.jacc.2019.07.020
- Corica B, Bonini N, Imberti JF, et al. Yield of diagnosis and risk of stroke with screening strategies for atrial fibrillation: a comprehensive review of current evidence. Eur Heart J Open. 2023;3(2):oead031. doi: 10.1093/ehjopen/oead031
- Gladstone DJ, Wachter R, Schmalstieg-Bahr K, et al. Screening for atrial fibrillation in the older population: a randomized clinical trial. JAMA Cardiol. 2021; 6(5):558–567. doi: 10.1001/jamacardio.2021.0038
- Seshadri DR, Bittel B, Browsky D, et al. Accuracy of apple watch for detection of atrial fibrillation. Circulation. 2020;141(8):702–703. doi: 10.1161/CIRCULATIONAHA.119.044126
- Kirchhof P, Toennis T, Goette A, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med. 2023;389(13):1167–1179. doi: 10.1056/NEJMoa2303062
- Healey JS, Lopes RD, Granger CB, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med. 2023;390(2):107–117.
- Lubitz SA, Atlas SJ, Ashburner JM, et al. Screening for atrial fibrillation in older adults at primary care visits: VITAL-AF randomized controlled trial. Circulation. 2022;145(13):946–954. doi: 10.1161/CIRCULATIONAHA.121.057014